Disrupting ATF4 Expression Mechanisms Provides an Effective Strategy for BRAF-Targeted Melanoma Therapy

Area of Science:

• Oncology
• Molecular Biology
• Cellular Signaling

Background:

• The BRAF V600 mutation is crucial in melanoma development.
• The function of oncogenic BRAF in adaptive stress responses remains unclear.

Purpose of the Study:

• To elucidate the role of oncogenic BRAF in adaptive stress response pathways.
• To identify potential therapeutic targets within this pathway.

Main Methods:

• Investigated the interplay between BRAF, GCN2 kinase, and ATF4 under nutrient and therapeutic stress.
• Utilized mTOR and eIF4B as downstream regulators in signaling pathway analysis.
• Screened for compounds inhibiting the GCN2-ATF4 pathway during BRAF inhibitor treatment.

Main Results:

• Oncogenic BRAF is essential for ATF4 induction via GCN2 activation during stress.
• BRAF utilizes mTOR and eIF4B for ATF4 induction under GCN2 activation.
• The GCN2-ATF4 pathway remains active during BRAF inhibitor treatment, unlike the MEK-ERK pathway.
• A novel compound demonstrated synergistic cell killing with BRAF inhibitors by blocking GCN2-ATF4 activation.

Conclusions:

• Established a link between oncogenic BRAF and the GCN2-ATF4 adaptive stress response pathway.
• This collaboration presents a potential new therapeutic strategy targeting melanoma's adaptive stress mechanisms.